Search Result

Results for "

latency

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Adrenergic Receptor (1) Apoptosis (4) Autophagy (2) Bacterial (2) CDK (2) Cholecystokinin Receptor (2) Cholinesterase (ChE) (1) COX (2) Dopamine Receptor (1) EBV (4) Epigenetic Reader Domain (2) HDAC (4) Histamine Receptor (1) HIV (17) HSP (1) mAChR (1) mGluR (1) Neuropeptide Y Receptor (1) NF-κB (1) NO Synthase (2) Opioid Receptor (1) Orexin Receptor (OX Receptor) (1) PAI-1 (1) Parasite (2) PI3K (1) PKC (2) Proteasome (2) Reactive Oxygen Species (1) Sigma Receptor (1) Sodium Channel (1) TGF-beta/Smad (1) TGF-β Receptor (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Infection (21) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (9)

By Targets:

ADC Cytotoxin (1)

Adrenergic Receptor (1)

Apoptosis (4)

Autophagy (2)

Bacterial (2)

CDK (2)

Cholecystokinin Receptor (2)

Cholinesterase (ChE) (1)

COX (2)

Dopamine Receptor (1)

EBV (4)

Epigenetic Reader Domain (2)

HDAC (4)

Histamine Receptor (1)

HIV (17)

HSP (1)

mAChR (1)

mGluR (1)

Neuropeptide Y Receptor (1)

NF-κB (1)

NO Synthase (2)

Opioid Receptor (1)

Orexin Receptor (OX Receptor) (1)

PAI-1 (1)

Parasite (2)

PI3K (1)

PKC (2)

Proteasome (2)

Reactive Oxygen Species (1)

Sigma Receptor (1)

Sodium Channel (1)

TGF-beta/Smad (1)

TGF-β Receptor (2)

By Research Areas:

Cancer (14)

Cardiovascular Disease (1)

Infection (21)

Inflammation/Immunology (8)

Metabolic Disease (1)

Neurological Disease (9)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117724

AZ3976	PAI-1	Cardiovascular Disease
AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC₅₀ value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC₅₀ of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay .

HY-114268

BRD-K98645985 2 Publications Verification	HIV	Infection
BRD-K98645985 is a BAF (mammalian SWI/SNF) transcriptional repression inhibitor with an EC₅₀ of ~2.37 µM. BRD-K98645985 binds ARID1A-specific BAF complexes, prevents nucleosomal positioning, and potently reverses HIV-1 latency, without T cell activation or toxicity .

HY-19618

BRD3308	HDAC HIV Apoptosis	Infection Metabolic Disease
BRD3308 is a highly selective HDAC3 inhibitor with an IC₅₀ of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC₅₀ of 1.26 μM) or HDAC2 (IC₅₀ of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency .

HY-10896

JNJ-10397049 1 Publications Verification	Orexin Receptor (OX Receptor)	Neurological Disease
JNJ-10397049 is a potent and selective orexin 2 receptor (OX₂R) antagonist, with a pK_i of 8.3. JNJ-10397049 is 600-fold selective for the OX₂R over the OX₁R .

HY-155599

HIV-1 protease-IN-10	HIV PKC	Infection
HIV-1 protease-IN-10 (Compound 2) has HIV-1 latency reversing activity (IC₅₀: 0.22 μM). HIV-1 protease-IN-10 binds to the PKCδ C1b domain (IC₅₀: 0.69 μM). HIV-1 protease-IN-10 has stability against esterase-mediated hydrolysis .

HY-147552

HIV-1 inhibitor-35	HIV	Infection
HIV-1 inhibitor-35 (compound 74) is a potent HIV-1 inhibitor with EC₅₀s of 80 nM and 70 nM for LTR and CMV in HEK293 cells, respectively. HIV-1 inhibitor-35 has inhibitory activity against liver cancer cell HepG2 with a CC₅₀ of 40 nM. HIV-1 inhibitor-35 can be used as HIV-1 latency reversing agent .

HY-162077

HIV-IN-10	HIV	Infection
HIV-IN-10 is a HIV-1 latency reversing agent .

HY-163666

HIV-1 inhibitor-68	HIV PKC	Infection
HIV-1 inhibitor-68 (compound 26) is a protein kinase C (PKC) activator derivative with reversal activity in HIV-1 latency. HIV-1 inhibitor-68 may be able to eliminate cells latently infected with HIV-1, .

HY-P1920

*CEF19, Epstein-Barr Virus latent* NA-3A (458-466)**	EBV	Inflammation/Immunology
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .

HY-130997

17-GMB-APA-GA	ADC Cytotoxin HSP	Infection Cancer
17-GMB-APA-GA is an ADC Cytotoxin. 17-GMB-APA-GA is a potent HSP90 inhibitor and used for latent T. gondii infection research .

HY-103232

IEM-1925 bromide	mGluR	Neurological Disease
IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-129810

PD 135158 CAM 1028	Cholecystokinin Receptor	Neurological Disease
PD 135158 (CAM 1028) is a selective CCK_B receptor antagonist with an IC₅₀ of 2.8 nM against mouse cortex CCK_B. PD 135158 shows anxiolytic activity .

HY-P10607

IALYLQQNW	EBV	Cancer
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .

HY-P5470

LMP2A (426-434)	EBV	Others
LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

HY-147553

HIV-1 inhibitor-36	HIV	Infection
HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1. HIV-1 inhibitor-36 has the potential for further development as novel latency reversing agents .

HY-147554

HIV-1 inhibitor-37	HIV	Infection
HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1. HIV-1 inhibitor-37 has the potential for further development as novel latency reversing agents .

HY-147555

HIV-1 inhibitor-38	HIV	Infection
HIV-1 inhibitor-38 (Compound 91) is a potent HIV-1. HIV-1 inhibitor-38 has the potential for further development as novel latency reversing agents .

HY-155128

LANA-DNA-IN-2	Others	Infection
LANA-DNA-IN-2 (Compound 20) is a latency-associated nuclear antigen (LANA)-DNA interaction inhibitor. LANA-DNA-IN-2 can be used for research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection .

HY-15815

Bromosporine 3 Publications Verification	Epigenetic Reader Domain Apoptosis CDK HIV	Cancer
Bromosporine is a potent BET inhibitor with an IC₅₀ value of 2.1 μM for PCAF. Bromosporine can arrest cell cycle and induce apoptosis in cancer cells. Bromosporine exhibits excellent antitumor activity in xenograft mice model when combined with 5-FU (HY-90006). Bromosporine can increase CDK9 T-loop phosphorylation in HIV-1 latency models, resulting the protection of reactivate HIV-1 replication from latency. Bromosporine can be used to research colorectal cancer, acute myeloid leukemia (AML) and AIDS .

HY-113896

U-67827E	Cholecystokinin Receptor	Others
U-67827E is a cholecystokinin (CCK) agonist that decreases food intake over a prolonged period of time in baboons. U-67827E may affect the latency to food by inhibiting the movement of food in the stomach and magnifying a gastric distention signal .

HY-10224A

Panobinostat lactate Maximum Cited Publications 60 Publications Verification LBH589 lactate; NVP-LBH589 lactate	HDAC HIV Autophagy Apoptosis	Infection Cancer
Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .

HY-119490

UMB-136	Epigenetic Reader Domain HIV	Infection
UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb .

HY-12651

Primaquine diphosphate 4 Publications Verification Primaquine phosphate; Primaquine bisphosphate	Parasite	Infection Cancer
Primaquine diphosphate is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine diphosphate prevents relapse in vivax and ovale malaria .

HY-161243

AChE-IN-56	Cholinesterase (ChE)	Neurological Disease
AChe-IN-56 is an orally active inhibitor for acetylcholinesterase enzyme (AChE) with neuroprotective efficacy .

HY-12651R

Primaquine diphosphate (Standard)	Parasite	Infection Cancer
Primaquine (diphosphate) (Standard) is the analytical standard of Primaquine (diphosphate). This product is intended for research and analytical applications. Primaquine diphosphate is a potent antimalaria agent and a potent gametocytocide in falciparum malaria. Primaquine diphosphate prevents relapse in vivax and ovale malaria .

HY-122681

SR-16435	Opioid Receptor	Neurological Disease
SR-16435 is a nociceptin/orphanin FQ (NOP)/μ-opioid receptor partial agonist, with high binding affinity (NOP receptor K_i=7.49; μ-Opioid receptor K_i=2.70). SR-16435 can relieve pain .

HY-130514

SMAPP1	HIV CDK	Infection
SMAPP1 is an activator of protein phosphatase-1 (PP1). SMAPP1 increases phosphorylation of CDK9’s Ser90 and Thr186 residues, but not Ser175. SMAPP1 induces HIV-1 replication, upregulates HIV-1 transcription that led to the reactivation of latent HIV-1 provirus .

HY-A0139

Thiothixene NSC 108165; Navan; Navane	Sigma Receptor mAChR Histamine Receptor Dopamine Receptor Adrenergic Receptor	Others
Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.

HY-123671

CYM2503	Neuropeptide Y Receptor	Neurological Disease
CYM2503 is a putative GalR2-positive allosteric modulator. CYM2503 increases the latency to first electrographic seizure and decreases the total time in seizure. CYM2503 also attenuates electroshock-induced seizures in mice. Galanin receptors type 1 (GalR1) and/or type 2 (GalR2) represent unique pharmacological targets for the research of seizures and epilepsy .

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .

HY-10224

Panobinostat Maximum Cited Publications 60 Publications Verification LBH589; NVP-LBH589	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .

HY-13207

ONX-0914 10+ Cited Publications PR-957	Proteasome Bacterial HIV	Infection Inflammation/Immunology
ONX-0914 (PR-957) is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K_i=5.2 μM). ONX-0914 reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .

HY-N0396

Harpagoside 1 Publications Verification	COX NO Synthase	Inflammation/Immunology Cancer
Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .

HY-17032

Indeloxazine (rac)-AS1069562 free base; YM-08054 free base	Others	Neurological Disease
Indeloxazine ((rac)-AS1069562 free base) is a brain active compound with anti-amnesic activity. Indeloxazine significantly prolonged the step latency in senescence accelerated mice (SAM-P/8/Ta), indicating that it has a promoting effect on brain function. Indeloxazine has a broader pharmacology than piracetam and exhibits stronger anti-amnesic activity. Indeloxazine has also been used as an anticonvulsant compound, further supporting its potential use in neuroprotection and behavioral improvement .

HY-13207A

ONX-0914 TFA 10+ Cited Publications PR-957 TFA	Proteasome Bacterial HIV	Infection Inflammation/Immunology
ONX-0914 (PR-957) TFA is a selective inhibitor of low-molecular mass polypeptide-7 (LMP7), the chymotrypsin-like subunit of the immunoproteasome. ONX-0914 TFA blocks cytokine production and attenuates progression of experimental arthritis. ONX-0914 TFA is a noncompetitive irreversible inhibitor of the mycobacterial proteasome (K_i=5.2 μM). ONX-0914 TFA reactivates latent HIV-1 through p-TEFb activation mediated by HSF-1 .

HY-123295

HDAC3-IN-T247	HDAC	Infection Cancer
HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC₅₀ of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells .

HY-N0396R

Harpagoside (Standard)	COX NO Synthase	Inflammation/Immunology
Harpagoside (Standard) is the analytical standard of Harpagoside. This product is intended for research and analytical applications. Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

HY-122189

Akuammine (-)-Akuammine; Vincamajoridine	Others	Neurological Disease
Akuammine is an indole alkaloid that has been found in Picralima nitida and has analgesic activity. It selectively binds to the μ- and κ-opioid receptors over the δ-opioid receptor (Kis=0.3, 1.68, and 10.4 μM for the human receptors, respectively). Akuammine inhibits forskolin-induced cAMP production in HEK293 cells expressing human μ- or κ-opioid receptors (IC₅₀s=2.6 and 0.073 μM, respectively). It increases the latency to withdrawal in the tail-flick or hot plate test in mice when administered at a dose of 60 mg/kg.

HY-145432

PI3K-IN-28	PI3K	Cancer
PI3K-IN-28 (Compound 6c) is a potent inhibitor of PI3K. PI3K-IN-28 displays the most potent activity with lower toxic effects on MCF-10a. PI3K-IN-28 displays half-maximal inhibitory concentration (IC₅₀, μM) values of 5.8, 2.3, and 7.9. PI3K-IN-28 is the most potent one with a selectivity index (SI) of 39 and is considered as a latent lead for further optimization of anticancer agents .

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-A0068

Aurothioglucose 1 Publications Verification Gold thioglucose	NF-κB HIV Reactive Oxygen Species	Infection Inflammation/Immunology Cancer
Aurothioglucose (Gold thioglucose), containing monovalent gold ion, is a potent active-site inhibitor of TrxR1 (thioredoxin reductase 1), with an IC₅₀ of 65 nM. Aurothioglucose inhibits the DNA binding of NF-κB in vitro. Aurothioglucose shows anti-HIV and anti-rheumatic activities .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library	504 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID). MCE provides 504 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

JAK/STAT Compound Library

504 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 504 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P10607

IALYLQQNW	EBV	Cancer
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .

HY-P5470

LMP2A (426-434)	EBV	Others
LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

HY-P0299A

LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA) 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier .

HY-P0299

LSKL, Inhibitor of Thrombospondin (TSP-1) 10+ Cited Publications	TGF-β Receptor	Cancer
LSKL, Inhibitor of Thrombospondin (TSP-1) is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) can readily crosse the blood-brain barrier .

HY-P1920

*CEF19, Epstein-Barr Virus latent* NA-3A (458-466)**	EBV	Inflammation/Immunology
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). CEF19, Epstein-Barr Virus latent NA-3A (458-466) can significantly affect cytotoxic T-lymphocyte (CTL) recognition .

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-113896

U-67827E	Cholecystokinin Receptor	Others
U-67827E is a cholecystokinin (CCK) agonist that decreases food intake over a prolonged period of time in baboons. U-67827E may affect the latency to food by inhibiting the movement of food in the stomach and magnifying a gastric distention signal .

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of TGF-β1, and prevent the progression of hepatic damage and fibrosis .

Cat. No.	Product Name	Target	Research Area

HY-P990069

Linavonkibart	Inhibitory Antibodies	Cancer
Linavonkibart (SRK 181) is a high-affinity, fully human antibody that selectively binds to latent TGFβ1 and inhibits its activation. Linavonkibart plays an important role in cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0396

Harpagoside 1 Publications Verification	Structural Classification Iridoids Classification of Application Fields Terpenoids Pedaliaceae Plants Harpagophytum procumbens Inflammation/Immunology Disease Research Fields	COX NO Synthase
Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .

HY-N0396R

Harpagoside (Standard)	Structural Classification Iridoids Terpenoids Pedaliaceae Plants Harpagophytum procumbens	COX NO Synthase
Harpagoside (Standard) is the analytical standard of Harpagoside. This product is intended for research and analytical applications. Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .

Species:	Human (6) Mouse (1) Rat (1)
Tag:	His (2) Tag Free (4) Avi (1)
Source:	HEK293 (5) CHO (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70433

	TGF beta 1/TGFB1 LAP Protein, Human (HEK293) Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB	Human	HEK293
	TGF beta 1/TGFB1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. TGF beta 1 is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, apoptosis, and can regulate the expression and activation of other growth factors, including interferon gamma and tumor necrosis factor alpha. TGF beta 1/TGFB1 LAP Protein, Human (HEK293) is the recombinant human-derived TGF beta 1/TGFB1 LAP protein, expressed by HEK293 , with tag free. and C33S mutation.

HY-P71056

	TGF beta 1/TGFB1 Protein, Human (Biotinylated, HEK293, N-Avi) Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB	Human	HEK293
	TGF beta 1/TGFB1 Protein is initially identified as a growth factor that induces the growth of rodent fibroblasts. TGF beta 1/TGFB1 Protein inhibits the cell cycle in the G1 phase. TGF beta 1/TGFB1 is an endogenous factor controlling apoptosis in normal and pathological tissues. TGF beta 1/TGFB1 Protein, Human (Biotinylated, HEK293, N-Avi) is a recombinant protein (A279-S390) produced by HEK293 cells with Avi tag.

HY-P70236

	Latent TGF beta 1/TGFB1 Protein, Human (C33S, HEK293, His) rHuLatent TGF Beta-1-C33S, His; Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB	Human	HEK293
	Latent TGF beta 1/TGFB1 Protein is a large extracellular matrix protein and an associated ligand of fibrillinmicrofibrils. Latent TGF beta 1/TGFB1 Protein, Human (C33S, HEK293, His) is a recombinant Biotinylated protein (L30-S390) produced by HEK293 cells with His tag.

HY-P70543

	TGF beta 1/TGFB1 Protein, Human (HEK293) Maximum Cited Publications 20 Publications Verification Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta; TGF-beta-1	Human	HEK293
	TGF beta 1/TGFB1 Protein is initially identified as a growth factor that induces the growth of rodent fibroblasts. TGF beta 1/TGFB1 Protein inhibits the cell cycle in the G1 phase. TGF beta 1/TGFB1 is an endogenous factor controlling apoptosis in normal and pathological tissues. TGF beta 1/TGFB1 Protein, Human (HEK293) is a recombinant protein (A279-S390) produced by HEK293 cells.

HY-P70543G

	GMP TGF beta 1/TGFB1 Protein, Human (CHO) 1 Publications Verification Transforming Growth Factor Beta-1; TGF-Beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta; TGF-beta-1	Human	CHO
	TGF beta 1/TGFB1 Protein is initially identified as a growth factor that induces the growth of rodent fibroblasts. TGF beta 1/TGFB1 Protein inhibits the cell cycle in the G1 phase. TGF beta 1/TGFB1 is an endogenous factor controlling apoptosis in normal and pathological tissues. GMP TGF beta 1/TGFB1 Protein, Human (HEK293) is a GMP-grade recombinant protein (A279-S390) produced by CHO cells.

HY-P700150AF

	Animal-Free TGF beta 1/TGFB1 Protein, Human (His) Transforming Growth Factor beta-1; TGF-beta-1; latency-Associated Peptide; LAP; TGFB1; TGFB; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta; TGF-beta-1	Human	E. coli
	TGF beta 1/TGFB1 is a polypeptide member of the transforming growth factor beta superfamily of cytokines. TGF beta 1 is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation, apoptosis, and can regulate the expression and activation of other growth factors, including interferon gamma and tumor necrosis factor alpha. Animal-Free TGF beta 1/TGFB1 Protein, Human (His) is the recombinant human-derived animal-FreeTGF beta 1/TGFB1 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free TGF beta 1/TGFB1 Protein, Human (His) is 112 a.a., with molecular weight of ~13.7 kDa.

HY-P70648

	TGF beta 1/TGFB1 Protein, Mouse/Rat (HEK293) 5+ Cited Publications TGF-beta-1; CED; DPD1; TGFB; TGF-b1; TGFB1; CEDLAP; latency-associated peptide; TGFbeta; TGF-beta 1 protein; transforming growth factor beta-1; TGF-β1; TGF beta1; TGFbeta 1; TGF-beta 1; TGFbeta	Mouse;Rat	HEK293
	TGF beta 1/TGFB1 Protein, Mouse/Rat (HEK293), is a recombinant cytokine produced in HEK293 cells, is implicated as a key regulator of the development and cyclic remodelling characteristic of reproductive tissues.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks